Splanchnic vein thrombosis following renal transplantation: a case report

BMC Nephrology

Gulsum Akgun Cagliyan⁴  Ozgur Oztekin²  Funda Tasli¹  Ahmet Aykas⁵  Adam Uslu⁵  Erhan Tatar³ 

[1] Department of Pathology, Izmir Education and Research Hospital, Izmir, Turkey;Department of Radiology, Izmir Education and Research Hospital, Izmir, Turkey;Department of Nephrology and Transplantation Center, Izmir Education and Research Hospital, Izmir, Turkey;Department of Hematology, Izmir Education and Research Hospital, Izmir, Turkey;Department of General Surgery and Transplantation Center, Izmir Education and Research Hospital, Izmir, Turkey

关键词: Renal transplantation;    Myeloproliferative disorders;    JAK2 gene mutation;    Portosplenic vein thrombosis;    Thrombosis;   

Others  :  1082878
DOI  :  10.1186/1471-2369-14-161

 received in 2013-04-08, accepted in 2013-07-09,  发布年份 2013

【 摘 要 】

Background

Recurrent episodes of venous thrombosis have been closely correlated with JAK2 V617F mutation. Upto date, JAK2 gene mutation has not been defined as a prothrombic risk factor in renal transplant recipients. Herein; we present a case of portosplenic vein thrombosis in a primary renal transplant recipient with JAK2 V617F mutation who had no history of prior venous thromboembolism or thrombophilia.

Case presentation

A 59 year old female caucasian patient with primary kidney transplant admitted with vague abdominal pain at left upper quadrant. Abdominal doppler ultrasound and magnetic resonance imaging angiography demonstrated splanchnic vein thrombosis (SVT). The final diagnosis was SVT due to MPD (essential thrombocytosis, ET) with JAK2 V617F mutation. After 3 months of treatment with warfarin (≥5 mg/day, to keep target INR values of 1.9-2.5), control MRI angiography and doppler USG demonstrated partial (>%50) resolution of thrombosis with recanalization of hepatopedal venous flow. The patient is still on the same treatment protocol without any complication.

Conclusion

JAK2 V617F mutation analysis should be a routine procedure in the diagnosis and treatment of kidney transplant patients with thrombosis in uncommon sites.

【 授权许可】

   
2013 Tatar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jofre R, Lopez-Gomez JM, Moreno F, et al.: Changes in quality of life after renal transplantation. Am J Kidney Dis 1998, 32:93-100.
• [2]Poli D, Zanazzi M, Antonucci E, et al.: Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. J Thromb Haemost 2006, 4:988-992.
• [3]Kazory A, Ducloux D: Acquired hypercoagulable state in renal transplant recipients. J Thromb Haemost 2004, 91:646.
• [4]Heidenreich S, Junker R, Wolters H, et al.: Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003, 14:234-239.
• [5]Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683.
• [6]James C, Ugo V, Le Couedic JP, et al.: A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005, 434:1144-1148.
• [7]Baxter EJ, Scott LM, Campbell PJ, et al.: Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
• [8]De Stefano V, Fiorini A, Rossi E, et al.: Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007, 5:708-714.
• [9]De Stefano V, Martinelli I: Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010, 5:487-494.
• [10]Riva N, Donadini MP, Dentali F, et al.: Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 2012, 130(Suppl 1):S1-S3.
• [11]Donadini MP, Dentali F, Ageno W: Splanchnic vein thrombosis: new risk factors and management. Thromb Res 2012, 129(Suppl 1):S93-S96.
• [12]Irish AB, Green FR: Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997, 12:167-173.
• [13]Irish A: Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. Am J Cardiovasc Drugs 2004, 4:139-149.
• [14]Lijfering WM, de Vries AP, Veeger NJ, et al.: Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation. Thromb Haemost 2008, 99:127-132.
• [15]Trotter JF: Sirolimus in liver transplantation. Transplant Proc 2003, 35:193-200.
• [16]Ripert T, Menard J, Schoepen Y, et al.: Preventing graft thrombosis after renal transplantation: a multicenter survey of clinical practice. Transplant Proc 2009, 41:4193-4196.
• [17]Murashima M, Konkle BA, Bloom RD, et al.: A single-center experience of preemptive anticoagulation for patients with risk factors for allograft thrombosis in renal transplantation. Clin Nephrol 2010, 74:351-357.
• [18]Xavier SG, Gadelha T, Rezende SM, et al.: JAK2V617F mutation in patients with thrombosis: to screen or not to screen? Int J Lab Hematol 2011, 33:117-124.
• [19]Colaizzo D, Tiscia GL, Bafunno V, et al.: Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res 2011, 128:233-236.
• [20]Kiladjian JJ, Cervantes F, Leebeek FW, et al.: The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008, 111:4922-4929.
• [21]Austin SK, Lambert JR: The JAK2 V617F mutation and thrombosis. Br J Haematol 2008, 143:307-320.
• [22]Vannucchi AM: JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 2010, 5:22-28.
• [23]Xavier SG, Gadelha T, Pimenta G, et al.: JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 2010, 55:1770-1777.
• [24]Orr DW, Patel RK, Lea NC, et al.: The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010, 31:1330-1336.
• [25]Wüthrich RP, Cicvara-Muzar S, Booy C, Maly FE: Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2001, 72:549-550.